PHOENIX, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Morgan Stanley Global Healthcare Conference as follows:
|Date:||Tuesday, September 13, 2016|
|Time:||12:20 p.m. Eastern Daylight Time|
|Location:||Grand Hyatt, New York|
The presentations will be webcast live at the aforementioned times as well as archived for 90 days thereafter, via the Company’s website at www.insysrx.com, under the Investors Section.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROSTM (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.
SUBSYS® and SYNDROSTM are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Investor Contact: Lisa M. Wilson, President In-Site Communications, Inc. Phone: 212-452-2793 Email: email@example.com
Source:Insys Therapeutics, Inc.